Longeveron Inc. Files 8-K on Officer/Director Changes & Financials

TL;DR

Longeveron's leadership shuffle is official, with new directors/officers and compensation details filed.

AI Summary

Longeveron Inc. filed an 8-K on September 3, 2025, reporting on events that occurred on August 27, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates potential shifts in Longeveron's leadership and governance, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in key personnel and the reporting of financial statements can signal underlying business developments that may carry inherent risks.

Key Players & Entities

• Longeveron Inc. (company) — Registrant
• August 27, 2025 (date) — Date of earliest event reported
• September 3, 2025 (date) — Filing date
• Miami, Florida (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.001 — hich registered Class A Common Stock, $0.001 par value per share LGVN NASDAQ I
• $500,000 — be entitled to receive a base salary of $500,000, potential prorated target bonus paymen

Filing Documents

• ea0255905-8k_longeveron.htm (8-K) — 28KB
• ea025590501ex99-1_longever.htm (EX-99.1) — 18KB
• ex99-1_001.jpg (GRAPHIC) — 3KB
• 0001213900-25-084112.txt ( ) — 221KB
• lgvn-20250827.xsd (EX-101.SCH) — 3KB
• lgvn-20250827_lab.xml (EX-101.LAB) — 33KB
• lgvn-20250827_pre.xml (EX-101.PRE) — 22KB
• ea0255905-8k_longeveron_htm.xml (XML) — 4KB

02 Departure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2025, Longeveron Inc. (the "Company") and Wa'el Hashad, Chief Executive Officer, determined that Mr. Hashad would step down from his role as Chief Executive Officer and member of the Company's Board of Directors (the "Board"), effective immediately, so as to allow Mr. Hashad to pursue other opportunities. In connection with Mr. Hashad's departure, the Board has appointed Than Powell, the Company's current Chief Business Officer and head of business development, to serve as interim Chief Executive Officer, effective September 4, 2025, and until such time as a permanent successor has been identified. Further, the Board has appointed Dr. Joshua Hare, the Company's founder, Chief Science Officer and current Board Chair, as Executive Chairman of the Board. Mr. Powell, age 47, has over 25 years of pharmaceutical and biotech leadership across multiple industry-leading organizations, including GSK and Eli Lilly. Prior to Longeveron, Mr. Powell led Corporate Development & Strategy for Surescripts, ultimately resulting in the company's acquisition by TPG. Before that role, Mr. Powell was founder and CEO of Epulate, a venture-backed health technology company focused on Transplant Immunology. Mr. Powell holds a Bachelor of Arts in Economics from DePauw University and a Master of Business Administration from Stanford University, Graduate School of Business. In the role of interim Chief Executive Officer, Mr. Powell will be entitled to receive a base salary of $500,000, potential prorated target bonus payments at 60% of base salary, and an equity grant consisting of restricted stock units and stock options, subject to vesting. There are no arrangements or understandings between Mr. Powell and any other person pursuant to which he was selected as an officer. Mr. Powell has no direct or indirect material inte

View Full Filing

View this 8-K filing on SEC EDGAR